Jiangsu Aidea Pharmaceutical Group Co., Ltd. clinical trials
The registry lists 7 studies whose lead sponsor is Jiangsu Aidea Pharmaceutical Group Co., Ltd.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 7studies on the registry
- 3open to participants now
- 2reach primary completion within a year
Get an email when these change. Save the Jiangsu Aidea Pharmaceutical Group Co., Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 3 programmes
Each programme counted once, however many studies or names it has. 3 have a study Jiangsu Aidea Pharmaceutical Group Co., Ltd. leads, registered in the last two years.
All 3 programmes
The 3 programmes — sign in to see the list, free.
“Registry” is the highest phase of Jiangsu Aidea Pharmaceutical Group Co., Ltd.’s own registered studies; “Jiangsu Aidea Pharmaceutical Group Co., Ltd. says” is its pipeline, which lists phases by indication. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Jiangsu Aidea Pharmaceutical Group Co., Ltd.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
2 of Jiangsu Aidea Pharmaceutical Group Co., Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- 1JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
- Dec 2026Safety, Tolerability, and Pharmacokinetic Evaluation of ADB116 for InjectionNCT07729839
- Jun 2027Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance MutationsACC017 · NCT07711210
Add all 2 to your calendar (.ics) → With an account.
All 7 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 24
- 25
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Jiangsu Aidea Pharmaceutical Group Co., Ltd..
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.7 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 7 of 7.
- Single Ascending Dose Study of ACC085 Injection in Healthy Chinese AdultsRecruitingNCT07835633Phase 1
- Safety, Tolerability, and Pharmacokinetic Evaluation of ADB116 for InjectionRecruitingNCT07729839Phase 1
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)RecruitingNCT07711223Phase 1/2
- Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult ParticipantsCompletedNCT06278389Phase 1
- Phase Ib/IIa Clinical Study of ACC017 TabletsCompletedNCT06719310Phase 1/2
- Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting ConditionsCompletedNCT07753902Phase 1
- Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance MutationsActive, not recruitingNCT07711210Phase 1/2